The development phases I and II process for new oncological treatments generally take a similar format. The blog in this article we'll discuss the methods by which these studies are typically created, as well as newer approaches to increase the effectiveness of statistical analysis.
Phase 1 – Phase I usually consists of an in-depth dose-finding research with the intention of determining the most potent dose with toxicity limitations in the future phases II of the study. You can also search online to get more information about randomized stage ii clinical trials.
Image Source: Google
The randomized trials have almost always followed the 3+3 method where patients are recruited into cohorts of three, and then analyzed following the treatment to determine if they suffer from an adverse reaction called a dose-limiting toxicity (DLT) which are atypically toxicities that are serious and could not be accepted in the event that the toxicity is demonstrated in a large number of patients.
The MTD is typically the dose at which there is a maximum of 1 DLT over six patients. However, it will vary based on the patient population and the disease being studied, for instance in cancer , there is usually more tolerance to toxicities.
So, the development time of a study conducted using CRM is sure to be improved by having the research, statistical, and clinical teams working together to create the right specification for the subject and the trial being studied.